A biotech feud over the cancer blood test market

Plus: Novartis gets extended approval for breast cancer therapy

September 20, 2024 Check out STAT+

Sponsored By

NIH/NCI Center for Cancer Research STAT+ | Biotech feud over the multibillion-dollar cancer blood test market spills onto social media Guardant Health co-CEO offers $1 million bet to Exact Sciences CEO that early results of new colon cancer test won't hold up in larger trial By Jonathan Wosen FDA awards Novartis expanded approval for breast cancer therapy The potential market for the drug, Kisqali, could grow markedly, now that certain early-stage breast cancer patients will be able to receive it. By Angus Chen STAT+ | House panel passes pediatric rare disease bill, setting it up for government funding bill The bill would extend a controversial voucher program that promotes drug development for rare pediatric diseases for five years. By John Wilkerson and Jason Mast Graeme Jennings/Pool via AP Q&A: Former NIH director Francis Collins on a Trump administration, science, and God Among other things, Collins talked about how the National Institutes of Health might fare under another Trump administration. By Brittany Trang Opinion: The U.S. should follow California's lead on banning toxic chemicals in IV bags and tubes California is poised to ban DEHP, a cancer-causing chemical, from IV bags and tubes. The U.S. should follow. By Lisa Bailey

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser